Why Hoth Therapeutics (HOTH) stock jumped today?

Follow us on Google News:
 Why Hoth Therapeutics (HOTH) stock jumped today?
Image source: PopTika,Shutterstock

Highlights

  • The company reported positive results regarding the efficacy of HT-ALZ.

  • The data was generated using an Alzheimer's disease mouse model.

  • Hoth Therapeutics reported a net loss of US$3.29 million, or US$0.14 per share, for the quarter ended Sept 30, 2021.

Shares of Hoth Therapeutics, Inc. (NASDAQ: HOTH) jumped more than 102% on Tuesday after reporting the proof-of-concept data supporting the efficacy of its Alzheimer's drug HT-ALZ.

The data was generated using an Alzheimer's disease mouse model. The New York-based company develops therapies for atopic dermatitis, psoriasis, acne, etc.

The HT-ALZ therapeutic is being developed “under the 505 (b) (2) regulatory pathway” to treat dementia, the company said in a statement.


Hoth Therapeutics is conducting the study in collaboration with Washington University.

Also Read: US manufacturing PMI falls in December, factory activities up

Alzheimer's is a neurodegenerative disease distinguished by the aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain that causes dementia.

The research to assess the efficacy of orally administered HT-ALZ to reduce the Aβ concentration in the brain interstitial fluid was done by using an established Alzheimer's Disease mouse model (aged APP/PS1+/-mice). Meanwhile, the initial data from the study showed a remarkable decline in Aβ after extensive treatment with HT-ALZ.

Also Read: Why is PancakeSwap (CAKE) token up today?

Hoth Therapeutics (HOTH) stocks soars after reporting positive results on the efficacy of HT-ALZ

Source: Pixabay

Also Read: Why Keep Network (KEEP) crypto jumped over 12% today?

Stock performance, financials of Hoth Therapeutics, Inc. (NASDAQ: HOTH)


The stock traded at US$1.43 at 9:59 am ET on Jan 4, up 102.95% from its previous close. It has a market cap of US$34.26 million, with a forward one-year P/E ratio of -1.07. Its EPS is US$-0.56.

The stock’s highest price was US$3.50, and the lowest price was US$0.64 in the last 52 weeks. Its trading volume on Jan 3 was 302,553. The HOTH stock fell 13.82% in the past six months.

For the quarter ended Sept 30, 2021, it reported a net loss of US$3.29 million, or US$0.14 per share, against a loss of US$2.11 million, or US$0.16 per share in the same quarter of 2020.

Also Read: Apple becomes first company to top US$3 trillion in market value

Bottomline


Hoth chief scientific officer, Stefanie Johns, lauded the positive results stating that it is the "first step but a big one" in the development process of HT-ALZ. The healthcare sector has been in focus, in recent months, because of the COVID-19 pandemic.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.